HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $21

Benzinga Newsdesk www.benzinga.com Positive 54.9%

Neg 0% Neu 0% Pos 54.9%

HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from $17 to $21.